Regarding methods:
Primary outcome: In addition to an OGTT, 3-7 days of continuous glucose monitoring could be of great interest, to see how often reactive hypoglycemia occurs in everyday life. Only rarely do RYGB or SG operated subjects ingest 75 grammes of glucose dissolved in water over 10 min.
Secondary outcome: insulin sensitivity after the two surgeries: The matsuda insulin sensitivity index derived from an OGTT has not been validated in RYGB or SG operated individuals. In our hands the matsuda index of peripheral insulin sensitivity increases signigficantly one week after RYGB surgery, but when we do a hyperinsulinaemic euglycemic clamp, peripheral insulin sensitivity does not change. Thus, the current protocol has limitations with regards to assesing insulin sensitivity post op in the two groups.
Secondary outcome: severe hypoglycemia -recorded how? Questionaire or medical records or both? Will low blood glucose be documented.
Regarding the primary outcome measure: The incidence of hypoglycemia after RYGB compared to the incidence of hypoglycemia after SG. How is hypoglycemia defined. The authors write that different definitions of reactive hypoglycemia has been applied. It is not clear from the protocol which one they will use.
GENERAL COMMENTS
The study protocol titled"Randomized clinical study comparing the effect of Roux-en-Y gastric bypass and sleve gastrectomy on reactive hypoglycemia", Mingrone et al. describe a randomized controlled study in which they wish to investigate the occurrence of reactive hypoglycemia in a group of RYGB or SG operated subjects. A quick search on gastric bypass and sleeve gastrectomy reveals about 20 studies where effects of the two procedures has been compared, only a few of these are controlled clinical trials, only one study examine hypoglycemia (Roslin M et. al, Comparison Between RYGB, DS, and VSG Effect on Glucose Homeostasis, Obes Surg, 2012 jun 9 [Epub ahead of print]) in a comparative manner before and 6 months after surgery only. The comparison of LSG and RYGB is interesting from a physiological point of view as the two types of surgeries have many similar effects, but one bypasses the proximal small intestine whereas the other doesn't. The role of such a bypass in humans, which has been discussed for a while, would be elucidated by comparing the effects of the two surgeries.
As the litterature in this field is sparse, and as such a study would provide new insight into post RYGB and SG glucose metabolism and the physiology of the GI tract, the results of this study should be very interesting. Regarding methods:
VERSION 1 -AUTHOR RESPONSE
The following sentence has been added at page 16: "The patients will be asked to monitor their blood glucose by a 7 points glucose profile (i.e. before and 2 hours after breakfast, lunch and dinner plus one control before bedding) randomly performed once a week".
Secondary outcome: insulin sensitivity after the two surgeries: The Matsuda insulin sensitivity index derived from an OGTT has not been validated in RYGB or SG operated individuals. In our hands the matsuda index of peripheral insulin sensitivity increases significantly one week after RYGB surgery, but when we do a hyperinsulinaemic euglycemic clamp, peripheral insulin sensitivity does not change. Thus, the current protocol has limitations with regards to assessing insulin sensitivity post op in the two groups. We agree with the Reviewer that the euglycemic clamp is a better method to measure the whole body insulin sensitivity, however, at page 16 there was written that insulin sensitivity will be measured by both an empirical method, such as the Matsuda Index, and a mathematical model of the oral glucose tolerance test (OGTT).
In the revised version we have specified that "Glucose and insulin concentrations will be fitted by the oral glucose minimal model after the OGTT".
We have modified the sentence at page 14 in "Incidence of severe hypoglycemia or related symptoms (shakiness, sweating, dizziness or light-headedness, confusion, difficulty speaking, weakness, syncope, epilepsy, seizures) assessed by questionnaire and blood glucose measurement (glucometer) or medical report within 5 years after surgery".
Regarding the primary outcome measure: The incidence of hypoglycemia after RYGB compared to the incidence of hypoglycemia after SG. How is hypoglycemia defined. The authors write that different definitions of reactive hypoglycemia has been applied. It is not clear from the protocol which one they will use. We would like to thank the Reviewer for this observation and we acknowledge that this point was not clear enough. Therefore the primary endpoint at pg. 14 was modified as follows: "Primary Endpoint: incidence of reactive hypoglycemia at 1 year after bariatric surgery. According to the American Diabetes Association, a "true" hypoglycemic episode is defined as a plasma glucose value <3.9 mmol/l with or without accompanying symptoms. This cutoff will be used after either an OGTT or a glucose profile".
Hoping that the present version might be suitable for publication, please accept my best regards. Yours sincerely, Geltrude Mingrone
